Compare Johnson & Johnson (JNJ) vs Riot Platforms Inc (RIOT) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

RIOT trades at $19.90, up 8.98% today but facing bearish technical signals with the stock trading below key resistance levels. The company reported a net loss of $663.18 million in 2025 with negative profit margins, though revenue reached $647.44 million. Analyst consensus remains overwhelmingly bullish with 94% buy ratings and a $27.86 price target, representing 40% upside potential from current levels.

While Wall Street maintains strong buy recommendations, RIOT faces significant fundamental challenges with persistent losses and negative cash flow from operations. The stock's investment case hinges on successful execution of the company's strategic pivot toward high-performance computing and data center expansion, though operational losses and competitive pressures present substantial risks to shareholder value.